Clinical Trials Browser

Terminated × INDUSTRY × Lapatinib × Clear all

NCT00963547 2024-06-04

MK-2206-015

Phase 1 Terminated

33 enrolled 13 charts

Breast Neoplasms

NCT01199367 2024-04-25

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT00272987 2023-04-28

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Phase 3 Terminated

63 enrolled 22 charts

Breast Neoplasms

NCT00251433 2023-03-31

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT02213042 2021-10-13

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Phase 2 Terminated

42 enrolled 13 charts

Breast Neoplasms

NCT00508274 2021-09-21

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

Phase 3 Terminated

52 enrolled 12 charts

Breast Neoplasms

NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Phase 2 Terminated

62 enrolled 25 charts

Breast Neoplasms, Diarrhea, Neoplasms

NCT00968968 2019-06-10

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Phase 3 Terminated

37 enrolled 11 charts

Carcinoma, Neoplasms

NCT00073008 2017-02-28

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

Phase 2 Terminated

131 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00634088 2016-03-10

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Phase 1 Terminated

13 enrolled 13 charts

Breast Neoplasms

NCT00437073 2015-10-15

Brain Metastases In ErbB2-Positive Breast Cancer

Phase 2 Terminated

22 enrolled 8 charts

Brain Neoplasms, Breast Neoplasms

NCT00709618 2014-07-14

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

Phase 2 Terminated

44 enrolled 11 charts

Breast Neoplasms

NCT00447226 2012-06-12

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

Phase 2 Terminated

32 enrolled 10 charts

GastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms

NCT00479856 2012-06-05

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Phase 2 Terminated

9 enrolled 7 charts

Breast Neoplasms

NCT00820924 2012-03-28

Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

Phase 2 Terminated

Breast Neoplasms

NCT00657137 2012-03-15

APRiCOT-B

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis